Loading...
Explore More at wakehealth.edu

Clinical and Translational Science Institute

Keywords
Last Name

John D. McConnell, M.D.

TitleExec Dir WF Hlthcare Ventures
InstitutionWake Forest School of Medicine
DepartmentWF Healthcare Ventures
Address
vCardDownload vCard
    Other Positions
    TitleExecutive Director
    InstitutionWake Forest School of Medicine
    DepartmentWF Healthcare Ventures


    Collapse Research 
    Collapse research activities and funding
    U01DK046437     (MCCONNELL, JOHN D)Sep 30, 1992 - Mar 31, 2004
    NIH/NIDDK
    MEDICAL THERAPY OF BENIGN PROSTATIC HYPERPLASIA
    Role: Principal Investigator

    P50DK047657     (MCCONNELL, JOHN D)Sep 30, 1993 - Aug 31, 2004
    NIH/NIDDK
    BENIGN AND MALIGNANT PROSTATE GROWTH
    Role: Principal Investigator

    R13DK056482     (MCCONNELL, JOHN D)Sep 1, 1999 - Jun 30, 2000
    NIH/NIDDK
    CONFERENCE--ADVANCES IN BENIGN PROSTATIC HYPERPLASIA RES
    Role: Principal Investigator

    U01DK063661     (LIN, VICTOR K)Sep 30, 2002 - Jun 30, 2007
    NIH/NIDDK
    MTOPS Prostate Samples Analysis Consortium
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol. 2012 Dec; 62(6):953-61. PMID: 22652152.
      View in: PubMed
    2. Marberger M, McConnell JD, Fowler I, Andriole GL, Bostwick DG, Somerville MC, Rittmaster RS. Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol. 2011 May 01; 29(13):1744-9. PMID: 21444877.
      View in: PubMed
    3. Kaplan SA, Roehrborn CG, McConnell JD, Meehan AG, Surynawanshi S, Lee JY, Rotonda J, Kusek JW, Nyberg LM. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol. 2008 Sep; 180(3):1030-2; discussion 1032-3. PMID: 18639298.
      View in: PubMed
    4. Malaeb BS, Rashid HH, Lotan Y, Khoddami SM, Shariat SF, Sagalowsky AI, McConnell JD, Roehrborn CG, Koeneman KS. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. Urol Oncol. 2007 Jul-Aug; 25(4):291-7. PMID: 17628294.
      View in: PubMed
    5. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol. 2007 Feb 01; 25(4):349-55. PMID: 17264329.
      View in: PubMed
    6. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006 Apr; 175(4):1422-6; discussion 1426-7. PMID: 16516013.
      View in: PubMed
    7. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006 Jan; 175(1):217-20; discussion 220-1. PMID: 16406915.
      View in: PubMed
    8. Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol. 2005 Dec; 174(6):2098-104. PMID: 16280736.
      View in: PubMed
    9. Lin VK, Wang SY, Boetticher NC, Vazquez DV, Saboorian H, McConnell JD, Roehrborn CG. Alpha(2) macroglobulin, a PSA binding protein, is expressed in human prostate stroma. Prostate. 2005 May 15; 63(3):299-308. PMID: 15611997.
      View in: PubMed
    10. Benaim EA, Karam JA, Soboorian MH, Roehrborn CG, McConnell JD, Lin V. The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate. 2004 Sep 01; 60(4):310-6. PMID: 15264242.
      View in: PubMed
    11. Khoddami SM, Shariat SF, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI, Roehrborn CG, Koeneman KS. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. BJU Int. 2004 Jul; 94(1):42-6. PMID: 15217428.
      View in: PubMed
    12. Lotan Y, Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Cadeddu JA, Sagalowsky AI, McConnell JD, Roehrborn CG. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol. 2004 Jun; 171(6 Pt 1):2209-14. PMID: 15126787.
      View in: PubMed
    13. Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004 Mar; 171(3):1194-8. PMID: 14767299.
      View in: PubMed
    14. Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, McConnell JD, Holmes MN, Roehrborn CG. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol. 2004 Mar; 171(3):1122-7. PMID: 14767284.
      View in: PubMed
    15. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18; 349(25):2387-98. PMID: 14681504.
      View in: PubMed
    16. Lotan Y, Roehrborn CG, McConnell JD, Hendin BN. Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. Urology. 2003 Nov; 62(5):918-21. PMID: 14624920.
      View in: PubMed
    17. Lai YJ, Pong RC, McConnell JD, Hsieh JT. Surrogate marker for predicting the virus binding of urogenital cancer cells during adenovirus-based gene therapy. Biotechniques. 2003 Jul; 35(1):186-90, 192-4. PMID: 12866420.
      View in: PubMed
    18. Bautista OM, Kusek JW, Nyberg LM, McConnell JD, Bain RP, Miller G, Crawford ED, Kaplan SA, Sihelnik SA, Brawer MK, Lepor H. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2003 Apr; 24(2):224-43. PMID: 12689743.
      View in: PubMed
    19. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperto-McGinely J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E, Waldstreicher J. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003 Apr; 61(4):791-6. PMID: 12670567.
      View in: PubMed
    20. Sherwood JB, McConnell JD, Vazquez DJ, Lin VK, Roehrborn CG. Heterogeneity of 5 alpha-reductase gene expression in benign prostatic hyperplasia. J Urol. 2003 Feb; 169(2):575-9. PMID: 12544310.
      View in: PubMed
    21. Roehrborn CG, McConnell JD, Saltzman B, Bergner D, Gray T, Narayan P, Cook TJ, Johnson-Levonas AO, Quezada WA, Waldstreicher J. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol. 2002 Jul; 42(1):1-6. PMID: 12121721.
      View in: PubMed
    22. Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, Sagalowsky AI, McConnell JD, Marston W, Leach FS. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer. 2002 Feb 01; 94(3):690-9. PMID: 11857301.
      View in: PubMed
    23. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J. The effect of finasteride in men with benign prostatic hyperplasia. 1992. J Urol. 2002 Feb; 167(2 Pt 2):1102-7; discussion 1108. PMID: 11905882.
      View in: PubMed
    24. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002 Feb; 8(2):514-9. PMID: 11839671.
      View in: PubMed
    25. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem. 2002 Apr 12; 277(15):12622-31. PMID: 11812785.
      View in: PubMed
    McConnell's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Physical Neighbors Expand Description
    _